Scientists have discovered a new link that could bring the scientific and medical community closer to understanding why glioblastoma, the most common malignant brain tumor, is deadlier in males than females.
Oct 18, 2021
0
20
Neoadjuvant immune checkpoint blockade (ICB) is a promising treatment for melanoma and other cancer types, and has recently been shown to provide a modest survival benefit for patients with recurrent glioblastoma. To improve ...
Jun 29, 2021
0
13
Despite access to some of the best possible medical care in the world, Senators John McCain and Edward Kennedy both died within 18 months of their diagnosis of glioblastoma, an aggressive form of brain cancer. While this ...
Apr 19, 2021
0
190
Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they've grown back, enabling up to 20% of patients to live well beyond predicted survival ...
Jan 13, 2021
0
50
The healing process that follows a brain injury could spur tumor growth when new cells generated to replace those lost to the injury are derailed by mutations, Toronto scientists have found. A brain injury can be anything ...
Jan 4, 2021
0
173
White blood cells are part of many immune system responses in the human body. New research shows that a specific type of those cells may cause brain cancer tissues to die—but that's not good news, according to researchers ...
Dec 7, 2020
0
37
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results ...
Nov 25, 2020
0
2
A laboratory test developed by a research team led by Johns Hopkins University bioengineers can accurately pinpoint, capture and analyze the deadliest cells in the most common and aggressive brain cancer in adults.
Oct 15, 2020
0
69
Many modern cancer drugs target a specific genetic mutation that is driving a particular cancer's runaway growth and division—such as the HER-2 protein in some breast cancers or EGFR in certain lung cancers.
Jul 30, 2020
0
91
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived ...
Jul 13, 2020
0
6
